Feng He

发表

Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways

Suxing Liu, Weikang Tao, R. Chowdhury, 2022, Frontiers in Immunology.

Discovery of SHR1653, a Highly Potent and Selective OTR Antagonist with Improved Blood-Brain Barrier Penetration.

Weikang Tao, Bin Wang, Hong I. Wan, 2019, ACS medicinal chemistry letters.

Discovery of NVP‐LEQ506, a Second‐Generation Inhibitor of Smoothened

John Green, J. Williams, B. Lagu, 2013, ChemMedChem.

1-amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity.

J. Williams, S. Peukert, R. Guo, 2009, Journal of medicinal chemistry.

A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3).

Xi-Ping Huang, B. Roth, P. Atadja, 2015, Angewandte Chemie.

Discovery of 2-(Ortho-Substituted Benzyl)-Indole Derivatives as Potent and Orally Bioavailable RORγ Agonists with Antitumor Activity.

Minsheng Zhang, Suxing Liu, B. Gui, 2021, Journal of medicinal chemistry.

Discovery of Potent and Selective Allosteric Inhibitors of Protein Arginine Methyltransferase 3 (PRMT3)

P. Atadja, E. Li, F. Liu, 2017, Journal of medicinal chemistry.

WITHDRAWN: Discovery of SHR1977: A highly potent and selective ROMK inhibitor.

Wei He, Weikang Tao, Jijun Yuan, 2016, Bioorganic & medicinal chemistry letters.

Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin's Lymphoma.

Minsheng Zhang, Weikang Tao, Xiao-dong Shen, 2018, ACS medicinal chemistry letters.

Discovery of SHR5133, a Highly Potent and Novel HBV Capsid Assembly Modulator.

Bin Wang, Weikang Tao, Jun Feng, 2022, ACS medicinal chemistry letters.

A method for estimating the risk of drug-induced phototoxicity and its application to smoothened inhibitors

William Egan, W. Egan, B. Lagu, 2011 .

Discovery of SHR0687, a Highly Potent and Peripheral Nervous System-Restricted KOR Agonist.

Ting Zhang, Weikang Tao, Bin Wang, 2020, ACS medicinal chemistry letters.

Discovery of Imidazoisoindole Derivatives as Highly Potent and Orally Active Indoleamine-2,3-dioxygenase Inhibitors.

Weikang Tao, Qiyue Hu, Wei-Li Peng, 2019, ACS medicinal chemistry letters.

Discovery of SHR2415, a Novel Pyrrole-Fused Urea Scaffold ERK1/2 Inhibitor.

Xin Li, Weikang Tao, Jun Feng, 2022, ACS medicinal chemistry letters.

Discovery of spiro amide SHR902275: A potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancers.

Yu Zhou, Suxing Liu, Weikang Tao, 2021, European journal of medicinal chemistry.

Discovery of Hydroxyamidine Derivatives as Highly Potent, Selective Indoleamine-2,3-dioxygenase 1 Inhibitors.

Weikang Tao, Hongbo Fei, Qiyue Hu, 2021, ACS medicinal chemistry letters.

Discovery of novel spiro compound as RAF kinase inhibitor with in vitro potency against KRAS mutant cancer.

Suxing Liu, Weikang Tao, Rumin Zhang, 2022, Bioorganic & medicinal chemistry letters.

Discovery of SHR5428 as a Selective and Noncovalent Inhibitor of CDK7.

Xun Li, Jun Feng, Minggang Hu, 2023, Bioorganic & Medicinal Chemistry Letters.

Discovery of SHR9352: A Highly Potent G Protein-Biased μ-Opioid Receptor Agonist

Wei He, Weikang Tao, Qiyue Hu, 2017, ACS omega.